Alexion Pharmaceuticals, Inc. is a global biopharmaceutical company focused on bringing hope to patients and families affected by rare diseases by delivering innovative, life-changing therapies.

Alexion is the global leader in complement biology with 20+ years of experience. The Company developed Soliris® (eculizumab), the world’s first and only approved complement inhibitor, for the treatment of patients with paroxysmal nocturnal hemoglobinuria (PNH), atypical hemolytic uremic syndrome (aHUS), and refractory generalized myasthenia gravis (gMG).* Alexion also has two highly innovative enzyme replacement therapies for patients with life-threatening and ultra-rare metabolic disorders: Strensiq® (asfotase alfa) for patients with hypophosphatasia (HPP) and Kanuma® (sebelipase alfa) for patients with lysosomal acid lipase deficiency (LAL-D).

**RESEARCH & DEVELOPMENT**

Alexion’s research and development programs aim to deliver innovative, life-changing therapies for patients with rare diseases. Our internal research efforts are focused on leveraging the Company’s experience in complement biology to pursue novel molecules and targets in the complement cascade. Alexion’s development efforts focus on the core therapeutic areas of hematology, nephrology, neurology, and metabolic disorders. This includes expanding Soliris into new indications as well as strengthening our clinical-stage pipeline through internal and external development opportunities.

**COMPANY INFORMATION**

- Founded: 1992
- NASDAQ: ALXN
- Website: alexion.com
- Alexion’s employees around the globe serve patients in more than 50 countries
- Alexion’s headquarters are currently in New Haven, Conn. In September 2017, the company announced that it would relocate its headquarters to Boston, Mass., by mid-2018
- New Haven, Conn., will serve as the Company’s Center of Excellence for its world-class complement research and process development teams, which are dedicated to advancing Alexion’s innovation engine
- Boston will become the primary site for Business Development, Communications, Commercial, Strategy, Development and Legal activity, and many other functions will have a presence in Boston

**AWARDS AND RECOGNITION**

* Soliris is approved in the European Union for the treatment of adult patients with refractory generalized myasthenia gravis (gMG) who are anti-acetylcholine receptor (AChR) antibody-positive. Marketing applications for Soliris for the treatment of patients with anti-AChR antibody-positive refractory gMG have been accepted for review in the U.S. and Japan.
Alexion has several programs currently in development:

- **Eculizumab for NMOSD**—Alexion is evaluating eculizumab as a potential treatment for patients with neuromyelitis optica spectrum disorder (NMOSD), an ultra-rare autoimmune neurological disorder, in the Phase 3 PREVENT study.

- **Eculizumab for AMR**—Alexion is investigating eculizumab in patients receiving kidney transplants who are at elevated risk of acute antibody-mediated rejection (AMR), a severe and potentially life-threatening condition that can lead to severe kidney allograft damage.

- **ALXN1210 for PNH**—Alexion is evaluating ALXN1210, a highly innovative, longer-acting anti-C5 antibody, administered intravenously every eight weeks in Phase 3 trials in patients with PNH.

- **ALXN1210 for aHUS**—Alexion is evaluating ALXN1210 administered intravenously every eight weeks in Phase 3 trials in patients with aHUS.

- **ALXN1210 Subcutaneous**—Alexion is progressing the development of a subcutaneous formulation of ALXN1210.

**SERVING PATIENTS**

Today, Alexion has global operations in place to serve patients in 50 countries. Our approach to serving patients is driven by education and a passion for understanding and meeting the unique needs of patients and families suffering from rare diseases. This includes disease education programs to raise awareness among physicians, and diagnostic initiatives to reduce the multi-year delays that patients with rare diseases often face, even when a safe and effective therapy is available.

Alexion works with private healthcare organizations, policymakers and governments around the world so that patients with rare diseases have access to the therapies they need. In the United States and Canada, we offer **OneSource**™, a personalized program that provides education, assistance with access, and treatment support for patients and their caregivers.

Alexion supports Patient Assistance Programs administered by independent, non-profit, charitable organizations. We also support advocacy groups and charitable foundations, as we know they are a critical part of supporting the patient community.

**MANUFACTURING**

Alexion’s manufacturing facilities produce commercial and clinical quantities of the Company’s therapies to ensure uninterrupted worldwide supply and to support our clinical development programs. In line with sound supply chain practices, Alexion also works with third-party providers for additional manufacturing, product filling, packaging, and labeling.

Alexion’s global supply chain and operations headquarters are located in Ireland, where the Company also has an aseptic vial fill-finish facility and is building state-of-the-art bulk biologics manufacturing facilities. Alexion also has manufacturing sites in the United States.

**OUR FUTURE**

As we look ahead, Alexion’s ambition is to be the global leader in rare diseases by leveraging our expertise in complement and our capabilities in the four core areas of hematology, nephrology, neurology, and metabolics. We are committed to bringing hope and innovation to patients and families who, today, face devastating and life-threatening consequences and have few, if any, effective treatment options. We are driven because we know people’s lives depend on our work.